CG Oncology, Inc. (CGON): Total Assets
$791.59M
As of 2025-12-31
$1.09B
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $791.59M | +4.9% | 2026-02-27, Balance as of period end |
| 2024-12-31 | $754.80M | +278.7% | 2026-02-27, Balance as of period end |
| 2023-12-31 | $199.30M | n/a | 2025-03-28, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $318.94M | -27.6% |
Compare CGON, OCGN, PRME, CRSP side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗